TY - JOUR
T1 - T-PLL
T2 - Another check on the venetoclax list?
AU - Bose, Prithviraj
AU - Konopleva, Marina Y.
N1 - Funding Information:
Conflict-of-interest disclosure: M.Y.K. reports receiving research support from AbbVie and Genentech, and consulting fees from Roche, AbbVie, and Genentech. P.B. declares no competing financial interests. n
Publisher Copyright:
© 2017 by The American Society of Hematology.
PY - 2017/12/7
Y1 - 2017/12/7
N2 - In this issue of Blood, Boidol et al report a highly T-cell prolymphocytic leukemia (T-PLL)-specific response to the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax in an ex vivo high-throughput drug screen, as well as partial remissions (PRs) in 2 patients with relapsed/refractory (R/R) T-PLL and high disease burden, both of whom were previously treated with multiagent chemotherapy and alemtuzumab.1
AB - In this issue of Blood, Boidol et al report a highly T-cell prolymphocytic leukemia (T-PLL)-specific response to the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax in an ex vivo high-throughput drug screen, as well as partial remissions (PRs) in 2 patients with relapsed/refractory (R/R) T-PLL and high disease burden, both of whom were previously treated with multiagent chemotherapy and alemtuzumab.1
UR - http://www.scopus.com/inward/record.url?scp=85037638411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037638411&partnerID=8YFLogxK
U2 - 10.1182/blood-2017-10-809673
DO - 10.1182/blood-2017-10-809673
M3 - Comment/debate
C2 - 29217697
AN - SCOPUS:85037638411
SN - 0006-4971
VL - 130
SP - 2447
EP - 2448
JO - Blood
JF - Blood
IS - 23
ER -